TREACE MEDICAL CONCEPTS, INC.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash and cash equivalents $18.1m $105.8m $19.5m $13.0m $11.3m $10.7m
Accounts receivable, net of allowance for credit losses of $1,824 and $1,326 as of December 31, 2025 and December 31, 2024, respectively $14.5m $18.6m $29.2m $38.1m $40.8m $42.2m
Inventories $7.8m $10.6m $19.3m $29.2m $39.3m $36.0m
Prepaid expenses and other current assets $593k $3.0m $3.6m $7.9m $5.7m $5.5m
Total current assets $41.0m $138.0m $133.4m $198.4m $161.4m $132.1m
Property and equipment, net $829k $2.8m $15.3m $22.3m $26.0m $29.8m
IIntangible assets, net of accumulated amortization of $2,375 and $1,425 as of December 31, 2025 and December 31, 2024, respectively $0 $9.0m $8.1m $7.1m
Goodwill $0 $12.8m $12.8m $12.8m
Operating lease right-of-use assets $0 $10.1m $9.3m $8.4m $7.6m
Marketable securities, short-term $0 $61.8m $110.2m $64.3m $37.7m
Other non-current assets, net of allowance for credit losses of $69 and $69 as of December 31, 2025 and December 31, 2024, respectively $0 $146k $146k $407k $1.2m
Other liabilities $339k $4.4m $510k $2.4m
Derivative liability on term loan $245k $173k $0
Operating lease liabilities, net of current portion $0 $15.5m $15.9m $15.9m $14.0m
Total stockholders’ equity $776k $93.1m $60.5m $137.9m $112.9m $87.3m
Total assets $41.8m $140.8m $159.0m $251.9m $217.1m $190.6m
Total liabilities and stockholders’ equity $41.8m $140.8m $159.0m $251.9m $217.1m $190.6m
Accounts payable $2.3m $4.1m $8.7m $11.8m $10.5m $6.7m
Accrued liabilities $1.8m $4.5m $6.2m $10.5m $7.2m $5.8m
Accrued commissions $3.5m $5.2m $7.4m $10.8m $10.1m $9.4m
Accrued compensation $2.2m $4.5m $7.7m $7.5m $6.6m $6.3m
Total current liabilities $11.6m $18.2m $30.2m $45.0m $34.9m $30.6m
Long-term debt, net $29.2m $29.4m $52.7m $53.0m $53.3m $55.6m
Other long-term liabilities $0 $37k $37k $3.0m
Total liabilities $41.0m $47.7m $98.5m $114.0m $104.2m $103.2m
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued as of December 31, 2025 and December 31, 2024 $7.9m $0 $0 $0 $0 $0
Common stock, $0.001 par value, 300,000,000 shares authorized; 64,029,378 and 62,385,101 shares issued as of December 31, 2025 and December 31, 2024, respectively $28k $45k $55k $62k $62k $64k
Additional paid-in capital $14.2m $134.9m $145.2m $272.0m $303.0m $337.4m
Accumulated deficit ($21.4m) ($41.9m) ($84.7m) ($134.2m) ($190.0m) ($249.0m)
Accumulated other comprehensive income (loss) $0 ($27k) $163k $97k $72k
Treasury stock, at cost; 165,513 and 23,391 shares as of December 31, 2025 and December 31, 2024, respectively $0 ($13k) ($281k) ($1.2m)